Genprex Inc

Research Genprex Inc (GNPX) on Bullrun: market cap USD 42.35M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 42.35M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 0-USD 16.23M-USD 15.31Mn/a-22.83USD 7.83Mn/aUSD 7.96M
FY2024USD 0-USD 21.39M-USD 17.92Mn/an/aUSD 1.60Mn/aUSD 1.62M
FY2023USD 0-USD 30.86Mn/an/a-41.5USD 6.74Mn/aUSD 7.42M
FY2022USD 0-USD 23.74M-USD 17.62Mn/an/aUSD 20.95Mn/aUSD 22.27M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 42.35Mn/an/an/a
20252025-12-31USD 5.76Mn/an/an/a
20242024-12-31USD 9.25Mn/an/an/a
20232023-12-29USD 13.66Mn/an/an/a
20222022-12-30USD 69.60Mn/an/an/a
20212021-12-31USD 62.62Mn/an/an/a

About Genprex Inc

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Genprex Inc's market cap?

Genprex Inc's market capitalization is USD 42.35M.

What does Genprex Inc do?

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form.